研究等業績 - その他 - 羽渕 友則
-
転移性去勢抵抗性前立腺癌(mCRPC)において初期ホルモン治療に対する「PSA kinetics」は予後予測因子である
濱野 逸人, 畠山 真吾, 成田 伸太郎, 高橋 正博, 櫻井 俊彦, 川村 貞文, 三塚 浩二, 土谷 順彦, 荒井 陽一, 羽渕 友則, 大山 力
泌尿器外科 ( 医学図書出版(株) ) 33 ( 臨増 ) 894 - 894 2020年06月
-
高齢外国人に起こったTURBT後の高熱と尿道周囲・陰嚢の激烈な炎症
久木元 隆, 沼倉 一幸, 山本 竜平, 奈良 健平, 神田 壮平, 齋藤 満, 成田 伸太郎, 井上 高光, 佐藤 滋, 羽渕 友則
泌尿器外科 ( 医学図書出版(株) ) 33 ( 臨増 ) 814 - 815 2020年06月
-
Narita S.
International Journal of Clinical Oncology ( International Journal of Clinical Oncology ) 25 ( 5 ) 912 - 920 2020年05月
PURPOSE: Clinical outcomes of patients with newly diagnosed metastatic hormone-naïve prostate cancer (mHNPC) and initially treated with androgen deprivation therapy (ADT) were evaluated. METHODS: The medical records of 605 consecutive mHNPC patients with initial ADT or combined androgen blockade (CAB) at nine study centers between 2008 and 2016 were retrospectively reviewed. Castration-resistant prostate cancer (CRPC)-free and overall survival (OS) were estimated by the Kaplan-Meier method. The association of pretreatment risk factors with CRPC-free survival and OS was evaluated by Cox proportional hazard models and differences in survival were classified by the number of risk factors. RESULTS: Median follow-up was 2.95 years, median CRPC-free survival was 21.9 months and median OS was 5.37 years. Multivariable analysis found that four risk factors, a Gleason score ≥ 9, lymph node metastasis, an extent of disease score ≥ 2, and serum LDH of > 220 IU were independently associated with both CRPC-free survival and OS. Median CRPC-free survival of low-risk patients with no or one factor was 86.5 months, 17.9 months in intermediate-risk patients with two or three factors, and 11.0 months in high-risk patients with four factors. Median OS was 4.72 years in intermediate- and 2.44 years in high-risk patients. It was not reached in low-risk patients. CONCLUSION: In this series, CRPC-free and OS of a subset of mHNPC patients in Japan who were treated with ADT or CAB had better CRPC-free and overall survivals in Japan. Risk-adapted treatment based on the presence of novel prognostic factors may be beneficial for selected mHNPC patients.
-
Matsumoto H.
International Journal of Urology ( International Journal of Urology ) 27 ( 5 ) 362 - 368 2020年05月
The Clinical Practice Guidelines for Bladder Cancer edited by the Japanese Urological Association were first published in 2009 and a revised edition was released in 2015. Four years has passed since the 2015 edition, and the clinical practice environment surrounding bladder cancer has drastically changed during that time. The main changes include: (i) insurance coverage of a new diagnostic method for non-muscle-invasive bladder cancer; (ii) insurance coverage of an immune checkpoint inhibitor in advanced and metastatic bladder cancer; and (iii) advances in robot-assisted radical cystectomy as a minimally invasive treatment for muscle-invasive bladder cancer. A paradigm shift in bladder cancer diagnosis and treatment is occurring day by day. Therefore, in this 2019 edition, while dealing with the above changes, we carefully selected clinical questions with clear evidence and included other clinically important points in the general statement. We also added a new chapter on rare cancers of the urinary tract. As a new method for the evaluation of study evidence level, we introduce "The Grading of Recommendations Assessment, Development and Evaluation" system modified to Japanese by the Medical Information Network Distribution Service.
-
Robot-assisted laparoscopic pyeloplasty for ureteropelvic junction obstruction with duplex system
Numakura K.
Urology Case Reports ( Urology Case Reports ) 30 101138 - 101138 2020年05月
Management of ureteropelvic junction obstruction with a duplex system is technically challenging even when laparoscopic procedure is the standard approach for ureteropelvic junction obstruction. The patient was an otherwise healthy 21-year-old woman who presented with symptomatic ureteropelvic junction obstruction with the duplex system, which was completely excised using a robot-assisted approach. Robotic assistance allows for proper tissue dissection, minimal manipulation of the normal ureter, and meticulous fine suturing and would overcome the potential challenges involved in the minimally invasive management of such complex anomalies as shown in this patient.
-
Kashima S.
iScience ( iScience ) 23 ( 4 ) 100998 - 100998 2020年04月
Current adoptive T cell therapies conducted in an autologous setting are costly, time consuming, and depend on the quality of the patient's T cells. To address these issues, we developed a strategy in which cytotoxic T lymphocytes (CTLs) are regenerated from iPSCs that were originally derived from T cells and succeeded in regenerating CTLs specific for the WT1 antigen, which exhibited therapeutic efficacy in a xenograft model of leukemia. In this study, we extended our strategy to solid tumors. The regenerated WT1-specific CTLs had a strong therapeutic effect in orthotopic xenograft model using a renal cell carcinoma (RCC) cell line. To make our method more generally applicable, we developed an allogeneic approach by transducing HLA-haplotype homozygous iPSCs with WT1-specific TCR α/β genes that had been tested clinically. The regenerated CTLs antigen-specifically suppressed tumor growth in a patient-derived xenograft model of RCC, demonstrating the feasibility of our strategy against solid tumors.
-
Matsuda Y.
BMC Cancer ( BMC Cancer ) 20 ( 1 ) 302 - 302 2020年04月
BACKGROUND: Although docetaxel-based chemohormonal therapy (CHT) is one of the standard treatments for castration-resistant prostate cancer (CRPC), pertinent biomarkers and precise mechanisms involved in the resistance for CHT for CRPC remain unknown. We investigated the relationship between chemohormonal resistance and the expression of steroid receptors and Hippo pathway proteins using a docetaxel-resistant prostate cancer (PCa) cell line and human PCa tissues in patients who underwent surgery with and without neoadjuvant therapy. METHODS: A docetaxel-resistant subline (22Rv1-DR) was generated to assess Hippo pathway protein expression and the effect of YAP1 inhibition on cellular characteristics. A tissue microarray with 203 cores from 70 high-risk localized PCa tissues was performed to assess steroid receptor and Hippo pathway protein expressions. RESULTS: Nuclear YAP (nYAP) expression was higher in 22RV-1-DR than in parental 22Rv-1 and YAP1 knockdown suppressed cell proliferation of 22Rv1-DR. Steroid receptor and Hippo pathway protein expressions varied among three different neoadjuvant groups, and nYAP1 expression was the highest in the CHT group. The patients with high nYAP in residual cancer after neoadjuvant CHT had a significantly higher biochemical recurrence (BCR) rate than those with low nYAP1. On multivariate analysis, the high nYAP1 was an independent prognostic factor for BCR. CONCLUSIONS: nYAP expression is a potential biomarker in high-risk patients treated with docetaxel-based CHT. Steroid receptors and Hippo pathway proteins may play a role in the chemohormonal resistance in advanced PCa.
-
Okita K.
Clinical Genitourinary Cancer ( Clinical Genitourinary Cancer ) 18 ( 2 ) e103 - e111 2020年04月
INTRODUCTION: We aimed to evaluate the treatment sequence for patients with metastatic castration-resistant prostate cancer (mCRPC) in real-world practice and compare overall survival in each sequential therapy. PATIENTS AND METHODS: We retrospectively evaluated 146 patients with mCRPC who were initially treated with androgen deprivation therapy as metastatic hormone-naive prostate cancer in 14 hospitals between January 2010 and March 2019. The agents for the sequential therapy included new androgen receptor-targeted agents (ART: abiraterone acetate or enzalutamide), docetaxel, and/or cabazitaxel. We evaluated the treatment sequence for mCRPC and the effect of sequence patterns on overall survival. RESULTS: The median age was 71 years. A total of 35 patients received ART-ART, 33 received ART-docetaxel, 68 received docetaxel-ART, and 10 received docetaxel-cabazitaxel sequences. The most prescribed treatment sequence was docetaxel-ART (47%), followed by ART-ART (24%). Overall survival calculated from the initial diagnosis reached 83, 57, 79, and 37 months in the ART-ART, ART-docetaxel, docetaxel-ART, and docetaxel-cabazitaxel, respectively. Multivariate Cox regression analyses showed no significant difference in overall survival between the first-line ART (n = 68) and first-line docetaxel (n = 78) therapies (hazard ratio [HR], 0.84; P = .530), between the ART-ART (n = 35) and docetaxel-mixed (n = 111) sequences (HR, 0.82; P = .650), and between the first-line abiraterone (n = 32) and first-line enzalutamide (n = 36) sequences (HR, 1.58; P = .384). CONCLUSION: The most prescribed treatment sequence was docetaxel followed by ART. No significant difference was observed in overall survival among the treatment sequences in real-world practice.
-
特集 ここが変わった! 膀胱癌診療-新ガイドラインを読み解く 膀胱癌の経過観察
成田 伸太郎, 松井 喜之, 都築 豊徳, 羽渕 友則
臨床泌尿器科 ( 株式会社医学書院 ) 74 ( 5 ) 320 - 325 2020年04月
-
A patient with synchronous bilateral low-grade upper tract urothelial carcinoma who underwent nephroureterectomy and total ureterectomy with ileal ureteric replacement.
Yoshinori Matsuda, Takamitsu Inoue, Atsushi Maeno, Atsushi Koizumi, Ryohei Yamamoto, Taketoshi Nara, Sohei Kanda, Kazuyuki Numakura, Mitsuru Saito, Shintaro Narita, Shigeru Satoh, Tomonori Habuchi
International cancer conference journal 9 ( 2 ) 82 - 87 2020年04月
We present the case of a synchronous bilateral low-grade upper-tract urothelial carcinoma patient who underwent left nephroureterectomy and right total ureterectomy with ileal ureteric replacement resulting in a favorable prognosis. A 66-year-old male presented with bilateral hydronephrosis. Computed tomography revealed left pelvic and right upper-middle ureteral tumors with no lymph node swelling or distant metastasis. The patient underwent a left nephroureterectomy with a bladder cuff, and histopathology revealed a low-grade urothelial carcinoma. Considering the contralateral low-grade nature as revealed in histopathology and the right retrograde ureterography being noninvasive, he underwent a right total ureterectomy with ileal ureteric replacement. Histopathology of the right ureter revealed a low-grade urothelial carcinoma. The patient successfully avoided an anephric status without renal function deterioration for 4 years with a transurethral resection for a recurrent small papillary bladder tumor on 18 months after the total ureterectomy.
-
CANDIDATE GENES INVOLVED IN A DEFUNCTIONALIZING AND REFUNCTIONALIZING URINARY BLADDER INDUCED BY ANURIA AND URINE REPERFUSION IN A RABBIT URINARY DIVERSION MODEL
Yusuke Kiso, Takamitsu Inoue, Kazutoshi Nishijima, Minguo Huang, Taketoshi Nara, Sohei Kanda, Kazuyuki Numakura, Mitsuru Saito, Shintaro Narita, Masaru Yoshizumi, Masahito Kawatani, Shigeru Satoh, Tomonori Habuchi
JOURNAL OF UROLOGY ( LIPPINCOTT WILLIAMS & WILKINS ) 203 E796 - E796 2020年04月
-
BCG膀胱内注入療法におけるレボフロキサシンの効果に関する検討 非盲検多施設共同無作為比較試験
沼倉 一幸, 小林 瑞貴, 石田 俊哉, 前野 淳, 岡根 克己, 本間 直子, 鈴木 一正, 下田 直威, 高橋 修平, 鈴木 丈博, 久保 恭平, 熊澤 光明, 高橋 佳子, 佐々木 隆聖, 福田 歴視, 武藤 弓奈, 奈良 健平, 神田 壮平, 黄 明国, 齋藤 満, 成田 伸太郎, 井上 高光, 羽渕 友則
泌尿器外科 ( 医学図書出版(株) ) 33 ( 4 ) 374 - 377 2020年04月
筋層非浸潤性膀胱癌に対するBCG膀胱内注入療法+レボフロキサシン(LVFX)併用の有用性を検証するため、多施設共同の非盲検無作為化比較試験を行った。BCG+LVFX併用群52例とBCG単独群48例で比較した結果、BCGの完遂率は2群間で有意差を認めなかったが、Grade2以上の発熱および頻尿の発生率はBCG+LVFX併用群で有意に少なかった。副次評価項目の無再発生存期間は2群間で有意差がなかったが、無進行生存期間および癌特異的生存期間はBCG+LVFX併用群で有意に良好であった。
-
PTENノックアウト前立腺癌マウスモデルにおいてラード食は全身炎症と腸内細菌叢の変化を介して前立腺癌進展を促進する
佐藤 博美, 成田 伸太郎, 山本 竜平, 小泉 淳, 奈良 健平, 神田 壮平, 沼倉 一幸, 齋藤 満, 井上 高光, 佐藤 滋, 吉岡 年明, 羽渕 友則
腸内細菌学雑誌 ( (公財)腸内細菌学会 ) 34 ( 2 ) 142 - 142 2020年04月
-
【ここが変わった!膀胱癌診療-新ガイドラインを読み解く】膀胱癌の経過観察
成田 伸太郎, 松井 喜之, 都築 豊徳, 羽渕 友則
臨床泌尿器科 ( (株)医学書院 ) 74 ( 5 ) 320 - 325 2020年04月
＜文献概要＞ポイント ・非浸潤性膀胱癌(NMIBC)において,初回治療後3ヵ月目に膀胱鏡検査を行い,その後はリスク分類に基づいた経過観察が推奨される.また,尿中分子マーカーや狭帯域光観察(NBI)は選択された症例において推奨される.・筋層浸潤性膀胱癌(MIBC)において,再発リスクに沿った経過観察を行うことが推奨されるが,明確な経過観察プロトコールは確立されていない.・NMIBCおよびMIBCともに上部尿路評価を行い,無症候性再発を早期に発見することは推奨されるが,明確な経過観察プロトコールは確立されていない.
-
IgG抗A抗体価4096倍で術前脱感作療法に難渋した1例
山本 竜平, 齋藤 満, 小泉 淳, 奈良 健平, 神田 壮平, 沼倉 一幸, 成田 伸太郎, 井上 高光, 佐藤 滋, 羽渕 友則
日本臨床腎移植学会プログラム・抄録集 ( (一社)日本臨床腎移植学会 ) 53回 192 - 192 2020年02月
-
RTC・移植医のパートナーシップで腎移植〜知ってた?!お互い悩んでいること〜 生体ドナーについて移植医が注意を払う事
齋藤 満, 佐藤 滋, 伊藤 歩, 相庭 結花, 瀬田川 美香, 立原 恵理子, 成田 伸太郎, 井上 高光, 羽渕 友則
日本臨床腎移植学会プログラム・抄録集 ( (一社)日本臨床腎移植学会 ) 53回 155 - 155 2020年02月
-
抗CMV-IgG抗体陰性レシピエントにおけるCMV治療法についての検討
提箸 隆一郎, 斎藤 満, 山本 竜平, 奈良 健平, 神田 壮平, 沼倉 一幸, 井上 高光, 成田 伸太郎, 羽渕 友則, 藤山 信弘, 佐藤 滋
日本臨床腎移植学会プログラム・抄録集 ( (一社)日本臨床腎移植学会 ) 53回 253 - 253 2020年02月
-
最近の腎移植後感染症-予防と治療- BKポリオーマウイルス関連腎症 臨床的危険因子
齋藤 満, 浦山 健, 提箸 隆一郎, 齋藤 拓郎, 山本 竜平, 沼倉 一幸, 井手野 祥次, 柚木 幹弘, 坂井 薫, 前野 英毅, 佐藤 滋, 羽渕 友則
日本臨床腎移植学会プログラム・抄録集 ( (一社)日本臨床腎移植学会 ) 53回 102 - 102 2020年02月
-
秋田大学における腎移植後の晩期臨床課題に対する取り組み
齋藤 満, 佐藤 滋, 羽渕 友則
日本臨床腎移植学会プログラム・抄録集 ( (一社)日本臨床腎移植学会 ) 53回 161 - 161 2020年02月
-
腎移植後のメタボ予防への取り組み 効果的な患者指導の検討
大張 千里, 佐藤 未菜弥, 小原 風花, 山本 竜平, 羽渕 友則
日本臨床腎移植学会プログラム・抄録集 ( (一社)日本臨床腎移植学会 ) 53回 233 - 233 2020年02月